Cargando…
A randomized, controlled, crossover pilot study of losartan for pediatric nonalcoholic fatty liver disease
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in children, and currently, there are no FDA-approved therapies. Plasminogen activator inhibitor-1 (PAI-1) is elevated in children with NAFLD and associated with increased disease severity. Losartan potassium (losa...
Autores principales: | Vos, Miriam B., Jin, Ran, Konomi, Juna V., Cleeton, Rebecca, Cruz, Jessica, Karpen, Saul, Rodriguez, Dellys Soler, Frediani, Jennifer K., McCracken, Courtney, Welsh, Jean |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5987658/ https://www.ncbi.nlm.nih.gov/pubmed/29992039 http://dx.doi.org/10.1186/s40814-018-0306-4 |
Ejemplares similares
-
Natural History of NAFLD Diagnosed in Childhood: A Single-Center Study
por: Cioffi, Catherine E., et al.
Publicado: (2017) -
Alanine Aminotransferase as a Monitoring Biomarker in Children with Nonalcoholic Fatty Liver Disease: A Secondary Analysis Using TONIC Trial Data
por: Arsik, Idil, et al.
Publicado: (2018) -
Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY)
por: Hirata, Takumi, et al.
Publicado: (2013) -
Erratum to “Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY)”
por: Hirata, Takumi, et al.
Publicado: (2014) -
Arsenic exposure and risk of nonalcoholic fatty liver disease (NAFLD) among U.S. adolescents and adults: an association modified by race/ethnicity, NHANES 2005–2014
por: Frediani, Jennifer K., et al.
Publicado: (2018)